2025
Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes
How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsCardiovascular risk factorsEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraThrombotic outcomesThrombotic riskRisk factorsDiagnosis of hematological malignanciesMyeloproliferative neoplasm subtypeIncreased risk of deathType 2 diabetes mellitusMyeloproliferative neoplasms diagnosisRetrospective cohort analysisSex-matched controlsManaging cardiovascular risk factorsAssociated with survivalImprove patient morbidityRisk of deathMF patientsHematologic malignanciesMPN diagnosisPatient morbidityDana-FarberArterial/venous thrombosis
2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.Peer-Reviewed Original ResearchConceptsRisk of bleedingClinically relevant nonmajor bleedingEssential thrombocythemiaBleeding riskPlatelet countCumulative incidenceDana-Farber Cancer Institute and Massachusetts General HospitalAssociated with acquired von Willebrand syndromeCumulative incidence of thrombosisCumulative incidence of bleedingIncreased bleeding riskIncidence of bleedingReduced bleeding riskVon Willebrand syndromeIncidence of thrombosisNonmajor bleedingDNMT3A mutationsMassachusetts General HospitalThrombotic eventsDana-FarberDiabetes mellitusBleedingPatientsRisk factorsTreatment decisions
2023
No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis
Venkat R, Redd R, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley C, Luskin M, Hobbs G, How J. No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis. Blood 2023, 142: 1839. DOI: 10.1182/blood-2023-187530.Peer-Reviewed Original ResearchClinically relevant non-major bleedingTreated with cytoreductionYear cumulative incidenceIncidence of bleedingCumulative incidence of bleedingEssential thrombocythemiaRate of bleedingCumulative incidenceDisease coursePlatelet countThrombotic riskET patientsDiabetes mellitusInitiation of cytoreductive therapyMultivariate analysisActivity levelsIncidence rate of bleedingMultivariable Fine-Gray modelsLow riskRisk factorsInternational Prognostic Score of thrombosisET diagnosisCumulative incidence of thrombosisInternational Society on ThrombosisIncreased incidence of bleedingCardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes
How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsEssential thrombocythemiaVariant allele fractionMyeloproliferative neoplasmsPolycythemia veraAcute myeloid leukemiaHistory of atherosclerotic diseaseMF patientsCV-RFCardiovascular risk factorsRisk of deathOverall survivalRisk factorsMPN diagnosisLeukemia progressionArterial thrombosisGenomic profilingHazard ratioAssociated with increased risk of deathAssociated with adverse outcomesAssociated with higher risk of deathAtherosclerotic diseaseAssociated with increased riskHigher risk of deathAssociated with higher risk
2021
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality
Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.Peer-Reviewed Original ResearchConceptsAdult acute myeloid leukemia patientsAcute myeloid leukemia patientsMemorial Sloan Kettering Cancer CenterCourse of COVID-19 infectionAssociated with increased odds of deathDiagnosis of AMLClinical course of COVID-19 infectionMyeloid leukemia patientsFlow nasal cannulaAssociated with increased oddsOdds of deathClinical courseHematologic malignanciesChronic leukemiaNasal cannulaLeukemia patientsCOVID-19 infectionMechanical ventilationPoor outcomeCancer CenterActive treatmentLeukemia subtypesRelated mortalityPatientsRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply